Ann: FDA Grants Orphan Drug Designation for Revascor, page-140

I should also correct you - none of this is hindsight.

I've been calling these issues correctly for years. That's foresight.

Maybe I'm wrong this time - bound to be eventually, right?

But the FDA will require the adult data before approving paeds for aGVHD.

MSB will struggle with funding the adult trials, and will need cap raises likely at progressively lower share prices - they couldn't even fill the raise they wanted last time, and they've got their principal repayments of their loan due starting this year.

The congenital hypoplastic left heart indication will require further trials, back pain and CHF require more trials - there is no medium or short term plan for financing their current expenses.

This is my outlook, I might be wrong. Haven't been yet.

This is absolutely not a company I will be betting on. Not financial advice, just my strategy.

For those new around here thinking about dipping a toe do your own research. Look at the track record. Look at what the independent experts say about the trial results (there are videos on YouTube).

Don't listen to anyone on the forum, and keep in mind these pom poms were waving all the way from $5 to $0.26. And they still are. Same people.

I wish I was short. I have no good reason to post here other than to counteract the nonsense I see.

Beware